Novartis, Bayer and Boehringer Ingelheim to showcase their commitment to a reimagined pharma industry

Reuters Events 11 - 22 October, 2021, Virtual
Board level executives from Novartis, Bayer and Boehringer Ingelheim, amongst many more, will showcase their long-term visions for healthcare as a response to the COVID-19 pandemic, by joining the speaker faculty at Reuters Events Pharma Europe 2021.

Reuters Events will bring together another 150 life sciences leaders as speakers, and thousands more executive attendees, to showcase the investments being made as the industry accelerates its digital transformation platform to ensure changes are embedded for long-term value for physicians and patients alike.

Blair Gottscho, Managing Director - Pharma, Reuters Events, said the pharma industry had responded well to the challenges of the pandemic, re-assessed operating models, and have found new ways to deliver for physicians, clinicians, providers, payers and patients alike.

"There is significant investment happening across the industry - in both people and technology - to create long-lasting, integrated and flexible systems and processes, that are helping to build a more sustainable healthcare systems.

"We're proud to be showcasing the best and brightest at Pharma Europe 2021. This is the global home for industry executives to set strategy post-pandemic.” Along with this investment, the industry is experiencing an acceleration in collaboration between functions within organizations. However, the environment for collaboration extends beyond company walls, as companies are increasingly forming partnerships that build value for all healthcare stakeholders.

Josh Bramwell, Head of Europe, Reuters Events, said the industry had stepped up to the challenges that the pandemic has created.

“Companies are now seeing collaboration as a competitive advantage," Bramwell said.

"They've looked to optimise pre-competitive opportunities with industry partners, foster long-term stakeholder partnerships to provide real-world patient value, and remove function silos to deliver an agile and efficient business model. These are the case studies that we'll be highlighting on stage at Pharma Europe 2021."

Reuters Events Pharma Europe has been running for 18 years and was previously known as eyeforpharma Barcelona.

You can learn more about Pharma Europe here: https://reutersevents.com/events/barcelona/

Most Popular Now

Therapy using dual immune system cells effectively…

A newly developed immunotherapy that simultaneously uses modified immune-fighting cells to home in on and attack two antigens, or foreign substances, on cancer cells was ...

How to develop new drugs based on merged datasets

Polymorphs are molecules that have different molecular packing arrangements despite identical chemical compositions. In a recent paper, researchers at GlaxoSmithKline (GS...

New drug combination effective against SARS-CoV-2 …

More countries with greater resources are opening up for a more normal life. But COVID-19 and the SARS-CoV-2 virus are still a significant threat in large parts of the wo...

Cleveland Clinic study suggests steroid nasal spra…

A recent Cleveland Clinic study found that patients who regularly use steroid nasal sprays are less likely to develop severe COVID-19-related disease, including a 20 to 2...

Sanofi to focus its COVID-19 development efforts o…

Recent positive interim results of Sanofi's mRNA-based COVID-19 vaccine candidate Phase 1/2 study confirm the company's platform robust capabilities and strategy in mRNA...

Discovery of mechanics of drug targets for COVID-1…

A team of international researchers, including McGill Professor Stéphane Laporte, have discovered the working mechanism of potential drug targets for various diseases suc...

Phase II/III trial shows Ronapreve™ (casirivimab a…

Roche (SIX: RO, ROG; OTCQX: RHHBY) today confirmed positive data from the phase II/III 2066 study, investigating Ronapreve™ (casirivimab and imdevimab) in patients hospit...

Pfizer and BioNTech receive first U.S. FDA Emergen…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced that the U.S. Food and Drug Administration (FDA) has authorized for emergency use a booster dose of the P...

AZD7442 request for Emergency Use Authorization fo…

AstraZeneca has submitted a request to the US Food and Drug Administration (FDA) for an Emergency Use Authorization (EUA) for AZD7442, its long-acting antibody (LAAB) com...

Pfizer and BioNTech receive CHMP positive opinion …

Pfizer Inc. (NYSE: PFE, "Pfizer") and BioNTech SE (Nasdaq: BNTX, "BioNTech") today announced that the Committee for Medicinal Products for Human Use (CHMP) of the Europea...

GSK welcomes WHO recommendation for broad roll-out…

GlaxoSmithKline (GSK) plc welcomes and applauds the WHO recommendation for the broader deployment of GSK's RTS,S malaria vaccine to reduce childhood illness and deaths fr...

Boehringer Ingelheim acquires Abexxa Biologics to …

Boehringer Ingelheim announced the acquisition of Abexxa Biologics Inc., a biopharmaceutical company taking a new approach in the fields of immuno-oncology and oncology r...